SCHEDULE: Toronto-Dominion Bank Discloses UroGen Pharma Stake

The Toronto-Dominion Bank and TD Securities Inc. have filed a Schedule 13G, reporting beneficial ownership of 5.4% of UroGen Pharma Ltd.'s ordinary shares as of March 31, 2026.

Summary

• The Toronto-Dominion Bank (TD Bank) and its subsidiary TD Securities Inc. (TDSI) have jointly filed a Schedule 13G, indicating their beneficial ownership of UroGen Pharma Ltd. ordinary shares.
• As of March 31, 2026, TD Bank beneficially owns 2,616,714 shares, representing a 5.4% stake in the company.
• TDSI beneficially owns 1,306 shares, with TD Bank being the sole owner of TDSI.
• TD Bank has sole voting and dispositive power over its directly held shares and indirectly over TDSI's shares, though it disclaims ownership of TDSI's shares beyond its pecuniary interest.
• Both entities certify that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of ownership by financial institutions and does not inherently signal positive or negative performance for UroGen Pharma Ltd.

Positives

• The filing confirms a significant institutional holding by a major financial institution, which can be seen as a vote of confidence in the company's underlying value.
• The reporting entities are established financial institutions, suggesting a stable and professional management of the investment.

Negatives

• The filing does not contain any negative financial results or operational challenges.
• The disclosure is a standard Schedule 13G filing, indicating a passive investment rather than active engagement or strategic partnership.

Risks

• The primary risk is the potential for the reporting persons to sell their stake, which could negatively impact the stock price.
• As a financial institution, TD Bank's investment strategy could change, leading to divestment.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the company. It is a disclosure of beneficial ownership.

Management Comments

• TD Bank and TDSI certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates a passive investment by major Canadian financial institutions in a biotechnology firm.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding may provide some comfort, but the passive nature of the investment means it's unlikely to directly influence company strategy.
• Creditors: No direct impact is indicated.
• Employees: No direct impact is indicated.
• Suppliers/Customers: No direct impact is indicated.

Next Steps

• The reporting persons will continue to hold their shares in UroGen Pharma Ltd. in the ordinary course of business.
• Further filings may be required if their beneficial ownership changes significantly.

Key Dates

Keywords

UroGen Pharma Ltd., Schedule 13G, The Toronto-Dominion Bank, TD Securities Inc., Beneficial Ownership, Ordinary Shares, SEC Filing, Institutional Investor